Premium
Acute myeloid leukemia therapy elicits durable complete response in chemoradio‐resistant metastatic paraganglioma
Author(s) -
Sait Sameer,
Kobos Rachel,
LaQuaglia Michael P.,
PanditTaskar Neeta,
Modak Shakeel
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26314
Subject(s) - medicine , daunorubicin , myeloid leukemia , oncology , cytarabine , etoposide , chemotherapy , refractory (planetary science) , clofarabine , salvage therapy , surgery , physics , astrobiology
Few effective therapeutic options exist for patients with metastatic paraganglioma (PGL). We report the case of a 16‐year‐old male who developed acute myeloid leukemia (AML) 30 months following the treatment for metastatic PGL. PGL had been refractory to 131 I‐meta‐iodobenzylguanidine and temozolomide therapy. However, there was a major reduction in primary tumor allowing its gross total resection, and complete resolution of metastatic disease following AML‐directed therapy that included daunorubicin, cytarabine, and etoposide. He remains in remission for both AML and PGL, 48 months post AML chemotherapy. Alternative chemotherapeutic agents should be considered for metastatic PGL resistant to conventional therapy.